Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

When the FDA reviewed the data, updated analyses at 36 weeks demonstrated that dupilumab improved outcomes compared with placebo. 1 Specifically, 18.3% of patients on dupilumab achieved sustained ...

Between baseline and week 12, researchers additionally found a comparable level of improvement in prebronchodilator FEV 1 with dupilumab vs. placebo when split into those with emphysema (least ...

The association between dupilumab and psoriasis was further supported by validation in patients with asthma without atopic dermatitis (HR 2.13, 95% CI 1.38-3.31), the authors noted.

Importantly, like dupilumab, DC-15442 does not degrade STAT6 proteins or impair uSTAT6 non-inflammatory functions. Therefore, DC-15442 does not have the on-target safety concerns of potential ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color Provided by GlobeNewswire Jun 7, 2025, 3:30:00 PM ...

Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Glycosylation is the reaction catalysed by glycosyltransferases, which adds carbohydrates site-specifically to another molecule, generally proteins and lipids. Glycosylation comes in five forms: N ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.